Business · 04/06/2010

FDA Clears Cysteine HCl for Approval After Determination of No Safety or Effectiveness Concerns

The FDA has announced its determination that Cysteine Hydrochloride Injection, USP, 7.25% (Cysteine HCl), was not withdrawn from sale due to safety or effectiveness concerns, paving the way for potential approval of abbreviated new drug applications (ANDAs) for the medication.